You are here: Industry Insights > Breast Cancer

News List

Oncolytics Biotech Doses First Patient in Pelareorep-anti-PD-1 Study for Breast Cancer americanpharmaceuticalreview
August 27, 2020
Oncolytics Biotech® announced the first patient has been dosed in the Company's investigator-sponsored phase 2 study of pelareorep-anti-PD-1 combination therapy in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
Intraoperative radiotherapy as effective as external beam radiotherapy, finds study europeanpharmaceuticalreview
August 24, 2020
Researchers reveal that for early breast cancer a single dose of targeted intraoperative radiotherapy (TARGIT-IORT) is as effective at preventing breast cancer recurrence as the standard of care.
Single radiotherapy shot proves effective in breast cancer pharmatimes
August 21, 2020
A breast cancer therapy developed by UCL clinicians which requires just one shot of radiotherapy compared to the weeks-long treatment of current therapies been shown to be effective for most women.
Patent Awarded for Concarlo-Developed Therapeutic for Treatment-Resistant Breast Cancer americanpharmaceuticalreview
August 03, 2020
Concarlo announced that US Patent 10,702,570 was issued by the United States Patent and Trademark Office (USPTO) for a metastatic breast cancer treatment.
EU regulators approve Novartis' breast cancer combo pharmatimes
July 31, 2020
European regulators have approved Novartis' Piqray (alpelisib) in combination with fulvestrant for the treatment of a certain type of breast cancer.
Radiotherapy in fewer doses safe for early breast cancer pharmatimes
July 15, 2020
Giving fewer but larger doses of radiotherapy is as safe in the long term for breast cancer treatment, according to the final results of a 10-year study.
FDA Approves Home-Administered Breast Cancer Treatment americanpharmaceuticalreview
July 09, 2020
The U.S. Food and Drug Administration (FDA) has approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer.
FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional fda
July 06, 2020
The U.S. Food and Drug Administration approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body ...
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer pharmaceutical-business-review
July 06, 2020
Daiichi Sankyo Company announced the first patient with triple negative breast cancer (TNBC) has been dosed in the ongoing phase 1 study assessing DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC).
FDA Approves Pertuzumab, Trastuzumab, Hyaluronidase-zzxf Combination americanpharmaceuticalreview
July 01, 2020
The Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf (PHESGO, Genentech) for subcutaneous injection.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page